LRIG3 and central nervous system cancer: Besides, LRIG3 can inhibit activation of the Ras/ERK and PI3K/AKT pathways in glioma, indicating that LRIG3, similar to LRIG1, may have an antagonistic effect against LRIG2 (13, 14).